Summary

The plasma fractionation market is expected to reach USD 52.58 billion in 2031, up from USD 36.44 billion in 2026, at a CAGR of 7.6% over the forecast period. The market is primarily driven by rising demand for immunoglobulins across immunology and neurology, strategic expansion of plasma collection capacity by market players, and greater use of plasma-derived therapies. Immunoglobulins, including IVIG and SCIG, are widely used to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions, supporting sustained demand for plasma-derived products. In addition, companies are expanding plasma collection networks and investing in fractionation and manufacturing facilities to secure the source-plasma supply and increase production capacity. Advances in plasma collection, fractionation, chromatography, and downstream purification are improving plasma utilization and the recovery of therapeutic proteins, including immunoglobulins, albumin, and coagulation factors. However, market growth remains constrained by high treatment costs and reimbursement constraints for plasma-derived products, particularly for long-term therapies requiring repeated administration. Differences in healthcare coverage, reimbursement policies, and patient affordability across countries can limit access to plasma-derived therapies, affecting adoption and creating challenges for market expansion while maintaining product quality, safety, and supply continuity.

Immunoglobulins segment holds the largest share of the market
The immunoglobulins segment accounts for the largest share of the plasma fractionation market, driven by the increasing use of IVIG, SCIG, and other immunoglobulins to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions. Immunoglobulins play a critical role in immunology and neurology, and recurring treatment needs support sustained demand for plasma-derived products. The growing prevalence of immune-mediated diseases, rising clinical adoption of immunoglobulin therapies, and continued investments in plasma collection and fractionation capacity are expected to further strengthen this segment's position.

Therapeutics segment holds the largest share of the market
The therapeutics segment accounts for the largest share of the plasma fractionation market, driven by the widespread clinical use of plasma-derived medicinal products across immunology, neurology, hematology, critical care, and pulmonology. Therapeutic applications are critical to treating immunodeficiencies, autoimmune and neurological disorders, bleeding disorders, and other conditions requiring plasma-derived therapies. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors, along with rising healthcare utilization and investments in plasma-derived product manufacturing, continues to strengthen this segment's position.

US is expected to grow at the highest CAGR during the forecast period
The US is expected to post the highest CAGR in the plasma fractionation market, driven by a strong plasma collection infrastructure, an established presence of leading plasma fractionation companies, and high utilization of plasma-derived therapies. Rising demand for immunoglobulins, coagulation factor concentrates, albumin, and other plasma-derived products across therapeutic applications is supporting market growth. Growing investments in plasma collection capacity, fractionation and manufacturing facilities, and domestic supply capabilities are further strengthening the market. In addition, increasing adoption of advanced fractionation, purification, and high-concentration immunoglobulin formulations is expected to support demand across hospitals, specialty clinics, home care settings, and infusion centers.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side – 70% and Demand Side– 30%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (US), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) are among the key companies offering plasma fractionation products.

Research Coverage
This research report categorizes the plasma fractionation market by product (Immunoglobulins [IVIG, SCIG, and other Immunoglobulins], Coagulation factor concentrates [Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin complex concentrates, Factor XIII, and other coagulation factor concentrates], albumin, protease inhibitors, and other plasma products), application (therapeutics and academics & preclinical research), therapeutic area (neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications), end user (hospitals & specialty clinics, homecare settings & infusion centers, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report’s scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the plasma fractionation market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments related to the plasma fractionation market. This report also includes a competitive analysis of emerging startups in the plasma fractionation industry ecosystem.

Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Analysis of key drivers (Growing demand for immunoglobulins across immunology and neurology, Strategic expansion of plasma collection capacity by market players, Growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency, Increasing utilization of albumin in critical care), restraints (High treatment costs and reimbursement constraints for plasma-derived products, Market disruption caused by recombinant alternatives), opportunities (Government strategies for increasing regional self-sufficiency in plasma fractionation), and challenges (Stringent government regulations for maintaining safety and quality of plasma-derived products) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the plasma fractionation market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (USA), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) among others, in the plasma fractionation market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 40
1.3.4 CURRENCY CONSIDERED 40
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 41

2 EXECUTIVE SUMMARY 42
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 42
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS IN PLASMA FRACTIONATION MARKET 45
2.4 HIGH-GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47

3 PREMIUM INSIGHTS 48
3.1 PLASMA FRACTIONATION MARKET OVERVIEW 48
3.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION 49
3.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
3.4 PLASMA FRACTIONATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%) 50

4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Growing demand for immunoglobulins across immunology
and neurology 53
4.2.1.2 Strategic expansion of plasma collection capacity by market players 53
4.2.1.2.1 Plasma collection-by volume 54
4.2.1.2.1.1 US 54
4.2.1.2.1.2 Canada 54
4.2.1.2.1.3 United Kingdom 55
4.2.1.2.1.4 Japan 55
4.2.1.2.1.5 India 55
4.2.1.2.1.6 Brazil 56
4.2.1.3 Growing prevalence of respiratory diseases and alpha-

1 antitrypsin deficiency 56
4.2.1.4 Increasing utilization of albumin in critical care 57
4.2.2 RESTRAINTS 57
4.2.2.1 High treatment costs and reimbursement constraints for plasma-derived products 57
4.2.2.2 Market disruption caused by recombinant alternatives 58
4.2.3 OPPORTUNITIES 58
4.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation 58
4.2.4 CHALLENGES 59
4.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products 59
4.3 UNMET NEEDS & WHITE SPACES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61

5 INDUSTRY TRENDS 62
5.1 PORTER’S FIVE FORCES ANALYSIS 62
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 63
5.1.2 BARGAINING POWER OF SUPPLIERS 63
5.1.3 BARGAINING POWER OF BUYERS 64
5.1.4 THREAT OF SUBSTITUTES 64
5.1.5 THREAT OF NEW ENTRANTS 64
5.2 MACROECONOMIC OUTLOOK 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS & FORECAST 65
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 65
5.2.4 TRENDS IN GLOBAL BIOPHARMA INDUSTRY 66
5.3 VALUE CHAIN ANALYSIS 66
5.4 ECOSYSTEM ANALYSIS 68
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 70
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 71
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 72
5.6 TRADE ANALYSIS 74
5.6.1 IMPORT SCENARIO (HS CODE 3002.12) 74
5.6.2 EXPORT SCENARIO (HS CODE 3002.12) 75
5.7 KEY CONFERENCES & EVENTS, 2026–2027 76
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.9 INVESTMENT & FUNDING SCENARIO 78
5.10 CASE STUDY ANALYSIS 79
5.10.1 UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS 79
5.10.2 TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM 79
5.10.3 ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING 79
5.11 IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET 80
5.11.1 INTRODUCTION 80
5.11.2 KEY TARIFF RATES 80
5.11.3 PRICE IMPACT ANALYSIS 81
5.11.4 IMPACT ON COUNTRY/REGION 82
5.11.4.1 US 82
5.11.4.2 Europe 82
5.11.4.3 Asia Pacific 83
5.11.5 IMPACT ON END-USE INDUSTRIES 83
5.11.5.1 Hospitals & specialty clinics 83
5.11.5.2 Homecare settings & infusion centers 84
5.11.5.3 Other end users 84

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 85
6.1 TECHNOLOGY ANALYSIS 85
6.1.1 KEY TECHNOLOGIES 85
6.1.1.1 Cohn’s cold ethanol plasma fractionation 85
6.1.1.2 Plasma fractionation by chromatography 85
6.1.1.3 Plasma separation by centrifugation 86
6.1.1.4 Plasma separation by depth filtration 86
6.1.2 COMPLEMENTARY TECHNOLOGIES 86
6.1.2.1 Facilitated subcutaneous infusion systems 86
6.1.2.2 Liquid-stable high-concentration (20%) formulations 86
6.1.2.3 Single-use bioprocessing & continuous chromatography 87
6.1.3 ADJACENT TECHNOLOGIES 87
6.1.3.1 AI-driven analytics & smart fractionation yield optimization 87
6.1.3.2 Next-generation automated plasmapheresis & smart donor center systems 87
6.2 TECHNOLOGY ROADMAP 88
6.3 PATENT ANALYSIS 88
6.3.1 METHODOLOGY 88
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 88
6.3.3 LIST OF KEY PATENTS 89
6.4 FUTURE APPLICATIONS 90
6.5 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET 91
6.5.1 TOP USE CASES & MARKET POTENTIAL 92
6.5.2 BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS 93
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET 93
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 94
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES 94

7 SUSTAINABILITY & REGULATORY LANDSCAPE 96
7.1 REGIONAL REGULATIONS & COMPLIANCE 96
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
7.1.2 INDUSTRY STANDARDS 99
7.1.2.1 North America 99
7.1.2.2 Europe 99
7.1.2.3 Asia Pacific 100
7.1.2.4 Rest of the World 100
7.2 SUSTAINABILITY INITIATIVES 101
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 101
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 102

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105
8.1 DECISION-MAKING PROCESS 105
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 105
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 105
8.2.2 KEY BUYING CRITERIA, BY END USER 106
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 108
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109

9 PLASMA FRACTIONATION MARKET, BY PRODUCT 110
9.1 INTRODUCTION 111
9.2 IMMUNOGLOBULINS 111
9.2.1 IVIG 115
9.2.1.1 Expanding clinical indications, rising immune disorder diagnoses, and advances in IVIG formulations to drive market growth 115
9.2.2 SCIG 118
9.2.2.1 Rising preference for home-based treatment, expanding neurological indications, and patient-friendly administration to drive SCIG demand 118
9.2.3 OTHER IMMUNOGLOBULINS 122
9.3 COAGULATION FACTOR CONCENTRATES 126
9.3.1 FACTOR VIII 129
9.3.1.1 Improved hemophilia diagnosis and reliable plasma-derived product supply to boost demand for Factor VIII 129
9.3.2 FACTOR IX 133
9.3.2.1 Hemophilia B diagnosis and continued demand for replacement therapy to support Factor IX utilization 133
9.3.3 VON WILLEBRAND FACTOR 136
9.3.3.1 Expanded pediatric prophylaxis and increasing access to specialized bleeding disorder care to support market growth 136
9.3.4 PROTHROMBIN COMPLEX CONCENTRATES (PCC) 140
9.3.4.1 Rapid anticoagulation reversal and rising emergency-care requirements to aid market growth 140
9.3.5 FIBRINOGEN CONCENTRATES 143
9.3.5.1 Rising demand for targeted coagulation replacement to drive global market growth 143
9.3.6 FACTOR XIII 147
9.3.6.1 Growing demand for preventive replacement therapy to support market growth 147
9.3.7 OTHER COAGULATION FACTOR CONCENTRATES 150
9.4 ALBUMIN 153
9.4.1 RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH 153
9.5 PROTEASE INHIBITORS 157
9.5.1 INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET 157
9.6 OTHER PLASMA PRODUCTS 161

10 PLASMA FRACTIONATION MARKET, BY APPLICATION 165
10.1 INTRODUCTION 166
10.2 THERAPEUTICS 166
10.2.1 STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET 166
10.3 ACADEMICS & PRECLINICAL RESEARCH 170
10.3.1 EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND 170

11 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA 174
11.1 INTRODUCTION 175
11.2 NEUROLOGY 175
11.2.1 GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION 175
11.3 IMMUNOLOGY 178
11.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS 178
11.4 HEMATOLOGY 182
11.4.1 RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS 182
11.5 CRITICAL CARE 185
11.5.1 ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS 185
11.6 PULMONOLOGY 189
11.6.1 GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS 189
11.7 HEMATO-ONCOLOGY 192
11.7.1 INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS 192
11.8 RHEUMATOLOGY 195
11.8.1 EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS 195
11.9 OTHER THERAPEUTIC AREAS 199

12 PLASMA FRACTIONATION MARKET, BY END USER 203
12.1 INTRODUCTION 204
12.2 HOSPITALS & SPECIALTY CLINICS 204
12.2.1 INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS 204
12.3 HOME CARE SETTINGS & INFUSION CENTERS 207
12.3.1 GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES 207
12.4 OTHER END USERS 211

13 PLASMA FRACTIONATION MARKET, BY REGION 214
13.1 INTRODUCTION 215
13.2 NORTH AMERICA 216
13.2.1 US 220
13.2.1.1 Expanding plasma collection, fractionation capacity, and immunoglobulin demand to drive US market growth 220
13.2.2 CANADA 223
13.2.2.1 Rising immunoglobulin demand and investments in domestic plasma supply to drive market growth 223
13.3 EUROPE 226
13.3.1 GERMANY 229
13.3.1.1 Expanding plasma collection infrastructure and rising demand for plasma-derived therapies to drive market growth in Germany 229
13.3.2 UK 232
13.3.2.1 Rising immunoglobulin demand, domestic plasma collection, and investments in fractionation capacity to boost market growth 232
13.3.3 FRANCE 235
13.3.3.1 Established healthcare infrastructure and public plasma donation model to support access to treatment 235
13.3.4 ITALY 239
13.3.4.1 Growing use of immunoglobulins for neurological and immunological disorders to drive demand 239
13.3.5 SPAIN 241
13.3.5.1 Growing utilization of albumin for critical care and coagulation factor concentrates for bleeding disorders to support growth 241
13.3.6 REST OF EUROPE 244
13.4 ASIA PACIFIC 248
13.4.1 CHINA 252
13.4.1.1 Large domestic donor-plasma collection network and manufacturers focused on expanding product availability to drive growth 252
13.4.2 JAPAN 254
13.4.2.1 Highly organized blood donation system and national focus on securing plasma for domestic therapeutic requirements to boost market 254
13.4.3 INDIA 257
13.4.3.1 Substantial unmet treatment needs and efforts to improve access to quality-assured plasma-derived medicines to drive growth 257
13.4.4 SOUTH KOREA 261
13.4.4.1 Domestic manufacturing expertise with investments in storage infrastructure and overseas contract manufacturing to expand market 261
13.4.5 AUSTRALIA 263
13.4.5.1 National self-sufficiency policy linking locally collected plasma with domestic manufacturing and patient supply to position Australia as major hub 263
13.4.6 VIETNAM 266
13.4.6.1 Improvements in healthcare access and growing awareness of plasma-derived therapies to support demand 266
13.4.7 MALAYSIA 269
13.4.7.1 Dependence on imported plasma-derived therapies to increase focus on plasma collection, contract fractionation, and long-term supply agreements 269
13.4.8 INDONESIA 272
13.4.8.1 Large patient population and increasing diagnosis of neurological and immunological disorders to support demand for immunoglobulins 272
13.4.9 REST OF ASIA PACIFIC 275
13.5 LATIN AMERICA 279
13.5.1 BRAZIL 281
13.5.1.1 Expanding local processing to create opportunities to improve plasma utilization and strengthen Brazil's biopharmaceutical supply chain 281
13.5.2 MEXICO 284
13.5.2.1 Broader national strategy to expand pharmaceutical manufacturing and reduce reliance on imported medicines to drive market 284
13.5.3 REST OF LATIN AMERICA 287
13.6 MIDDLE EAST 291
13.6.1 GCC COUNTRIES 293
13.6.1.1 Saudi Arabia 297
13.6.1.1.1 National objective of achieving self-sufficiency in plasma-derived medicines and reducing dependence on imported therapies to aid growth 297
13.6.1.2 UAE 300
13.6.1.2.1 Growing investment in pharmaceutical localization and efforts to strengthen national medicine security to boost growth 300
13.6.1.3 Rest of GCC Countries 302
13.6.2 TURKEY 305
13.6.2.1 Domestic fractionation investment, import substitution, and rising demand for plasma-derived therapies to drive growth 305
13.6.3 EGYPT 308
13.6.3.1 Domestic plasma self-sufficiency, expanding collection infrastructure, and investment in local fractionation to fuel market 308
13.6.4 REST OF MIDDLE EAST 311
13.7 AFRICA 315
13.7.1 INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET 315

14 COMPETITIVE LANDSCAPE 318
14.1 OVERVIEW 318
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026 318
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023–AUGUST 2026 318
14.3 REVENUE ANALYSIS, 2021–2025 320
14.4 MARKET SHARE ANALYSIS, 2025 321
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 323
14.5.1 STARS 324
14.5.2 EMERGING LEADERS 324
14.5.3 PERVASIVE PLAYERS 324
14.5.4 PARTICIPANTS 324
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 326
14.5.5.1 Company footprint 326
14.5.5.2 Region footprint 327
14.5.5.3 Product footprint 328
14.5.5.4 Therapeutic area footprint 329
14.5.5.5 Application footprint 330
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 331
14.6.1 PROGRESSIVE COMPANIES 331
14.6.2 RESPONSIVE COMPANIES 331
14.6.3 DYNAMIC COMPANIES 331
14.6.4 STARTING BLOCKS 331
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 333
14.6.5.1 Detailed list of key startup/SME players 333
14.6.5.2 Competitive benchmarking of startups/SMEs 334
14.7 COMPANY VALUATION & FINANCIAL METRICS 335
14.7.1 COMPANY VALUATION 335
14.7.2 COMPANY VALUATION 335
14.8 BRAND/PRODUCT COMPARISON 336
14.9 COMPETITIVE SCENARIO 337
14.9.1 PRODUCT LAUNCHES 337
14.9.2 DEALS 338
14.9.3 EXPANSIONS 339

15 COMPANY PROFILES 340
15.1 KEY PLAYERS 340
15.1.1 CSL 340
15.1.1.1 Business overview 340
15.1.1.2 Products offered 341
15.1.1.3 Recent developments 344
15.1.1.3.1 Product launches 344
15.1.1.3.2 Expansions 345
15.1.1.4 MnM view 345
15.1.1.4.1 Key strengths 345
15.1.1.4.2 Strategic choices 345
15.1.1.4.3 Weaknesses & competitive threats 346
15.1.2 GRIFOLS, S.A. 347
15.1.2.1 Business overview 347
15.1.2.2 Products offered 348
15.1.2.3 Recent developments 350
15.1.2.3.1 Product launches 350
15.1.2.3.2 Deals 350
15.1.2.3.3 Expansions 351
15.1.2.4 MnM view 351
15.1.2.4.1 Key strengths 351
15.1.2.4.2 Strategic choices 351
15.1.2.4.3 Weaknesses & competitive threats 351
15.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED 352
15.1.3.1 Business overview 352
15.1.3.2 Products offered 353
15.1.3.3 Recent developments 355
15.1.3.3.1 Product launches 355
15.1.3.3.2 Deals 355
15.1.3.3.3 Expansions 356
15.1.3.4 MnM view 356
15.1.3.4.1 Key strengths 356
15.1.3.4.2 Strategic choices 356
15.1.3.4.3 Weaknesses & competitive threats 356
15.1.4 OCTAPHARMA AG 357
15.1.4.1 Business overview 357
15.1.4.2 Products offered 358
15.1.4.3 Recent developments 359
15.1.4.3.1 Product launches 359
15.1.4.3.2 Expansions 359
15.1.4.4 MnM view 360
15.1.4.4.1 Key strengths 360
15.1.4.4.2 Strategic choices 360
15.1.4.4.3 Weaknesses & competitive threats 360
15.1.5 KEDRION S.P.A. 361
15.1.5.1 Business overview 361
15.1.5.2 Products offered 362
15.1.5.3 Recent developments 364
15.1.5.3.1 Product launches 364
15.1.5.3.2 Deals 364
15.1.5.3.3 Expansions 364
15.1.5.4 MnM view 365
15.1.5.4.1 Key strengths 365
15.1.5.4.2 Strategic choices 365
15.1.5.4.3 Weaknesses & competitive threats 365
15.1.6 LFB 366
15.1.6.1 Business overview 366
15.1.6.2 Products offered 366
15.1.6.3 Recent developments 367
15.1.6.3.1 Expansions 367
15.1.7 ADMA BIOLOGICS, INC. 368
15.1.7.1 Business overview 368
15.1.7.2 Products offered 369
15.1.7.3 Recent developments 370
15.1.7.3.1 Deals 370
15.1.8 SANQUIN 371
15.1.8.1 Business overview 371
15.1.8.2 Products offered 372
15.1.8.3 Recent developments 372
15.1.8.3.1 Expansions 372
15.1.9 TAIBANG BIOLOGICAL GROUP CO., LTD. 373
15.1.9.1 Business overview 373
15.1.9.2 Products offered 373
15.1.9.3 Recent developments 374
15.1.9.3.1 Expansions 374
15.1.10 GC BIOPHARMA CORPORATE 375
15.1.10.1 Business overview 375
15.1.10.2 Products offered 376
15.1.10.3 Recent developments 377
15.1.10.3.1 Product launches 377
15.1.10.3.2 Deals 377
15.1.10.3.3 Expansions 378
15.1.11 HUALAN BIOLOGICAL ENGINEERING INC. 379
15.1.11.1 Business overview 379
15.1.11.2 Products offered 379
15.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION 381
15.1.12.1 Business overview 381
15.1.12.2 Products offered 381
15.1.12.3 Recent developments 383
15.1.12.3.1 Product launches 383
15.1.12.3.2 Expansions 383
15.1.13 EMERGENT 384
15.1.13.1 Business overview 384
15.1.13.2 Products offered 385
15.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. 386
15.1.14.1 Business overview 386
15.1.14.2 Products offered 387
15.1.14.3 Recent developments 388
15.1.14.3.1 Deals 388
15.1.15 INTAS PHARMACEUTICALS LTD. 389
15.1.15.1 Business overview 389
15.1.15.2 Products offered 389
15.1.15.3 Recent developments 390
15.1.15.3.1 Deals 390
15.1.15.3.2 Expansions 390
15.2 OTHER PLAYERS 391
15.2.1 BHARAT SERUMS AND VACCINES LIMITED 391
15.2.2 SK PLASMA 392
15.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD. 393
15.2.4 KAMADA PHARMACEUTICALS 394
15.2.5 CENTURION 395
15.2.6 PLASMAGEN BIOSCIENCES PVT. LTD. 396
15.2.7 VIRCHOW BIOTECH 397
15.2.8 FUSION HEALTHCARE 397
15.2.9 ICHOR 398

16 RESEARCH METHODOLOGY 399
16.1 RESEARCH DATA 399
16.1.1 SECONDARY DATA 400
16.1.1.1 Key data from secondary sources 400
16.1.2 PRIMARY DATA 401
16.1.2.1 Key data from primary sources 401
16.1.2.2 Key primary participants 401
16.1.2.3 Breakdown of primary interviews 402
16.1.2.4 Key industry insights 403
16.2 MARKET SIZE ESTIMATION 404
16.2.1 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025 404
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION 407
16.3 MARKET GROWTH RATE PROJECTIONS 408
16.4 DATA TRIANGULATION 410
16.5 FACTOR ANALYSIS 411
16.6 RESEARCH ASSUMPTIONS 411
16.7 RESEARCH LIMITATIONS & RISK ASSESSMENT 412

17 APPENDIX 413
17.1 DISCUSSION GUIDE 413
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 416
17.3 CUSTOMIZATION OPTIONS 418
17.4 RELATED REPORTS 418
17.5 AUTHOR DETAILS 419

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 PLASMA FRACTIONATION MARKET SEGMENTATION & REGIONS CONSIDERED 39.
FIGURE 2 PLASMA FRACTIONATION MARKET: YEARS CONSIDERED 40.
FIGURE 3 MARKET SCENARIO 43.
FIGURE 4 GLOBAL PLASMA FRACTIONATION MARKET, 2024–2031 43.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2023–2026 44.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PLASMA FRACTIONATION MARKET 45.
FIGURE 7 HIGH-GROWTH SEGMENTS IN PLASMA FRACTIONATION MARKET, 2026–2031 46.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PLASMA FRACTIONATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 47.
FIGURE 9 RISING ADOPTION OF PLASMA-DERIVED PRODUCTS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH 48.
FIGURE 10 THERAPEUTICS ACCOUNTED FOR LARGEST SHARE OF PLASMA FRACTIONATION MARKET IN NORTH AMERICA IN 2025 49.
FIGURE 11 CHINA AND GERMANY LIKELY TO BE FASTEST-GROWING MARKETS IN.
GLOBAL PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD 49.
FIGURE 12 THERAPEUTICS TO DOMINATE MARKET DURING FORECAST PERIOD 50.
FIGURE 13 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 52.
FIGURE 14 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS 63.
FIGURE 15 PLASMA FRACTIONATION MARKET: VALUE CHAIN ANALYSIS 67.
FIGURE 16 PLASMA FRACTIONATION MARKET: ECOSYSTEM ANALYSIS 69.
FIGURE 17 AVERAGE SELLING PRICE OF PRODUCTS, 2025 (USD) 72.
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD) 73.
FIGURE 19 PLASMA FRACTIONATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77.
FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2024–2026 (USD MILLION) 79.
FIGURE 21 PATENT APPLICATIONS IN PLASMA FRACTIONATION MARKET,.
JANUARY 2015–DECEMBER 2025 89.
FIGURE 22 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET 92.
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 105.
FIGURE 24 KEY BUYING CRITERIA, BY END USER 106.
FIGURE 25 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT 216.
FIGURE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT 248.
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2021–2025 (USD MILLION) 320.
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION.
MARKET, 2025 321.
FIGURE 29 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 325.
FIGURE 30 PLASMA FRACTIONATION MARKET: COMPANY FOOTPRINT 326.
FIGURE 31 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 332.
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA.
OF KEY VENDORS 335.
FIGURE 33 EV/EBITDA OF KEY VENDORS 335.
FIGURE 34 PLASMA FRACTIONATION MARKET: BRAND/PRODUCT COMPARISON 336.
FIGURE 35 CSL: COMPANY SNAPSHOT (2025) 341.
FIGURE 36 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025) 348.
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2025) 353.
FIGURE 38 OCTAPHARMA AG: COMPANY SNAPSHOT (2025) 357.
FIGURE 39 KEDRION S.P.A.: COMPANY SNAPSHOT (2025) 362.
FIGURE 40 ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2025) 369.
FIGURE 41 SANQUIN: COMPANY SNAPSHOT (2025) 371.
FIGURE 42 GC BIOPHARMA CORPORATE: COMPANY SNAPSHOT (2025) 376.
FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025) 385.
FIGURE 44 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT (2025) 386.
FIGURE 45 PLASMA FRACTIONATION MARKET: RESEARCH DESIGN 399.
FIGURE 46 PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES 402.
FIGURE 47 PLASMA FRACTIONATION MARKET: INSIGHTS FROM PRIMARIES 403.
FIGURE 48 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025 404.
FIGURE 49 PLASMA FRACTIONATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 405.
FIGURE 50 ILLUSTRATIVE EXAMPLE OF CSL: REVENUE ANALYSIS (2025) 405.
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 407.
FIGURE 52 PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS 409.
FIGURE 53 PLASMA FRACTIONATION MARKET: DATA TRIANGULATION 410.
TABLE 1 PLASMA FRACTIONATION MARKET: INCLUSIONS & EXCLUSIONS 40.
TABLE 2 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 52.
TABLE 3 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021–2022 56.
TABLE 4 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES 62.
TABLE 5 PLASMA FRACTIONATION MARKET: ROLE OF PLAYERS IN ECOSYSTEM 70.
TABLE 6 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 (USD) 71.
TABLE 7 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 72.
TABLE 8 IMPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 74.
TABLE 9 EXPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 75.
TABLE 10 PLASMA FRACTIONATION MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–MARCH 2027 76.
TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US 80.
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 82.
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 88.
TABLE 14 LIST OF KEY PATENTS IN PLASMA FRACTIONATION MARKET, 2023–2025 89.
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET 93.
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES IN PLASMA FRACTIONATION MARKET 95.
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96.
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97.
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 106.
TABLE 22 KEY BUYING CRITERIA, BY END USER 106.
TABLE 23 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 111.
TABLE 24 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,.
2024–2031 (USD MILLION) 112.
TABLE 25 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION,.
2024–2031 (USD MILLION) 112.
TABLE 26 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 27 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 28 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 29 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 30 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 31 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 32 PLASMA FRACTIONATION MARKET FOR IVIG, BY REGION,.
2024–2031 (USD MILLION) 115.
TABLE 33 PLASMA FRACTIONATION MARKET FOR IVIG, 2024–2031 (METRIC TONS) 116.
TABLE 34 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 35 EUROPE: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,.
2024–2031 (USD MILLION) 116.
TABLE 36 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,.
2024–2031 (USD MILLION) 117.
TABLE 37 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,.
2024–2031 (USD MILLION) 117.
TABLE 38 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,.
2024–2031 (USD MILLION) 118.
TABLE 39 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 40 PLASMA FRACTIONATION MARKET FOR SCIG, BY REGION,.
2024–2031 (USD MILLION) 119.
TABLE 41 PLASMA FRACTIONATION MARKET FOR SCIG, 2024–2031 (METRIC TONS) 119.
TABLE 42 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 43 EUROPE: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,.
2024–2031 (USD MILLION) 120.
TABLE 44 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,.
2024–2031 (USD MILLION) 120.
TABLE 45 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 46 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,.
2024–2031 (USD MILLION) 121.
TABLE 47 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 48 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 49 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,.
2024–2031 (METRIC TONS) 123.
TABLE 50 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 51 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,.
BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 52 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 53 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 54 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 55 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 56 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 57 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 58 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 59 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 60 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 61 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 62 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 63 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 64 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION,.
2024–2031 (USD MILLION) 130.
TABLE 65 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, 2024–2031 (MILLION IU) 130.
TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,.
BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY,.
2024–2031 (USD MILLION) 131.
TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 70 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 71 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,.
BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 72 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION,.
2024–2031 (USD MILLION) 133.
TABLE 73 PLASMA FRACTIONATION MARKET FOR FACTOR IX, 2024–2031 (MILLION IU) 134.
TABLE 74 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 75 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 76 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 77 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 78 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 79 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 80 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 81 PLASMA FRACTIONATION MARKET FOR FACTOR VON WILLEBRAND FACTOR,.
2024–2031 (MILLION LITER) 137.
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 83 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR,.
BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 84 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 85 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 86 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 87 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 88 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 89 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, 2024–2031 (MILLION IU) 141.
TABLE 90 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 91 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 92 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 93 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 94 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 95 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 96 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2024–2031 (USD MILLION) 144.
TABLE 97 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,.
2024–2031 (MILLION IU) 144.
TABLE 98 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 99 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,.
BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 100 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 101 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 102 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 103 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 104 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION,.
2024–2031 (USD MILLION) 147.
TABLE 105 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, 2024–2031 (MILLION IU) 148.
TABLE 106 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,.
BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 107 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY,.
2024–2031 (USD MILLION) 148.
TABLE 108 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 109 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 110 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 111 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,.
BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY REGION, 2024–2031 (USD MILLION) 151.
TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 117 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 118 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 119 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION,.
2024–2031 (USD MILLION) 154.
TABLE 120 PLASMA FRACTIONATION MARKET FOR ALBUMIN, 2024–2031 (METRIC TONS) 154.
TABLE 121 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 122 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY,.
2024–2031 (USD MILLION) 155.
TABLE 123 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 124 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 125 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 126 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 127 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION,.
2024–2031 (USD MILLION) 158.
TABLE 128 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,.
2024–2031 (MILLION IU) 158.
TABLE 129 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 130 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,.
BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 131 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,.
BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 132 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,.
BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 133 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,.
BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 134 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 135 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 162.
TABLE 136 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 137 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS,.
BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 138 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 139 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 140 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 141 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 142 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 166.
TABLE 143 PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY REGION,.
2024–2031 (USD MILLION) 167.
TABLE 144 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 145 EUROPE: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 146 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 147 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 148 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 149 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 150 PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH,.
BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 151 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 152 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 154 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 155 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 156 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 157 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,.
2024–2031 (USD MILLION) 175.
TABLE 158 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION,.
2024–2031 (USD MILLION) 176.
TABLE 159 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 160 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 161 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 162 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 163 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 164 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 165 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION,.
2024–2031 (USD MILLION) 179.
TABLE 166 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 167 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 168 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 170 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 171 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 172 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION,.
2024–2031 (USD MILLION) 182.
TABLE 173 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 174 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 175 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 176 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 177 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 178 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 179 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION,.
2024–2031 (USD MILLION) 186.
TABLE 180 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,.
BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 181 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 182 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,.
BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 183 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,.
BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 184 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,.
BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 185 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,.
BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 186 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION,.
2024–2031 (USD MILLION) 189.
TABLE 187 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 188 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 189 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 190 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 191 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 192 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 193 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION,.
2024–2031 (USD MILLION) 192.
TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 198 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 199 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 200 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION,.
2024–2031 (USD MILLION) 196.
TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 202 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 203 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 204 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 205 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 206 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,.
BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 207 PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 199.
TABLE 208 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 209 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS,.
BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 210 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 212 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 213 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 214 PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION) 204.
TABLE 215 PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS,.
BY REGION, 2024–2031 (USD MILLION) 205.
TABLE 216 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 218 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 219 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 220 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 221 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 222 PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY REGION, 2024–2031 (USD MILLION) 208.
TABLE 223 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 224 EUROPE: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 225 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 226 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 227 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 228 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 229 PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY REGION,.
2024–2031 (USD MILLION) 211.
TABLE 230 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 231 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 232 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 233 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 234 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 235 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,.
BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 236 PLASMA FRACTIONATION MARKET, BY REGION, 2024–2031 (USD MILLION) 215.
TABLE 237 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 217.
TABLE 238 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 217.
TABLE 239 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,.
BY TYPE, 2024–2031 (USD MILLION) 217.
TABLE 240 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 241 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 218.
TABLE 242 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 219.
TABLE 243 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,.
2024–2031 (USD MILLION) 219.
TABLE 244 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 220.
TABLE 245 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,.
2024–2031 (USD MILLION) 220.
TABLE 246 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 247 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 221.
TABLE 248 US: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,.
2024–2031 (USD MILLION) 222.
TABLE 249 US: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION) 222.
TABLE 250 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 223.
TABLE 251 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION) 223.
TABLE 252 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 224.
TABLE 253 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 224.
TABLE 254 CANADA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,.
2024–2031 (USD MILLION) 225.
TABLE 255 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,.
2024–2031 (USD MILLION) 225.
TABLE 256 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 226.
TABLE 257 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 227.
TABLE 258 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION) 227.
TABLE 259 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 228.
TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 228.
TABLE 261 EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,.
2024–2031 (USD MILLION) 229.
TABLE 262 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,.
2024–2031 (USD MILLION) 229.
TABLE 263 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 230.
TABLE 264 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION) 230.
TABLE 265 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION) 231.
TABLE 266 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 231.
TABLE 267 GERMANY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,.
2024–2031 (USD MILLION) 232.
TABLE 268 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,.
2024–2031 (USD MILLION) 232.